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A simple, accurate, isocratic stability indicating RP‐HPLC method was developed for the determination 
of cefepime and amikacin in Pure and its pharmaceutical formulations. The method consists of methanol: 
acetonitrile:acetate buffer 75:20:05 (v/v) mobile phase at pH 5.1 with C18 column as stationary phase. 
The flow rate and detection wave length were 1.0 mL/min and 212 nm respectively. The linearity range 
for the method was found to be 2.5-25 µg/mL for amikacin and 10-100 µg/mL cefepime respectively. The 
developed method was validated as per ICH guidelines and the results of all the validation parameters 
were well within their acceptance values. Also the forced degradation studies were conducted with 
standard drugs. Degradation products formed during the different stress conditions were separated from 
both drugs. This validated method was applied for the simultaneous estimation of cefepime and amikacin 
in commercially available formulation sample. 
Keywords: Cefepime/method development and validation. Amikacin/method development and validation. 
RP-HPLC.
INTRODUCTION
Cefepime is a broad-spectrum cephalosporin 
antibiotic with greater activity against both gram-negative 
and gram-positive organisms than third-generation agents 
(Ahavet al., 2007; Chapman, Perry, 2003). Chemical 
name of the cefepime is (6R,7R)-7-[[(2Z)-2-(2-amino-
1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-
methyl pyrrolidin-1-ium-1-yl) methyl]-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-ene-2-carboxylate – Figure 1a 
(http://www.chemspider.com). It is a fourth-generation 
antibiotic used for treatment of pneumonia (moderate to 
severe) caused by Streptococcus pneumoniae, including 
cases associated with concurrent bacteremia, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, or Enterobacter 
species. Also for empiric treatment of febrile neutropenic 
patients and uncomplicated and complicated urinary tract 
infections (including pyelonephritis), uncomplicated skin 
and skin structure infections, complicated intra-abdominal 
infections (used in combination with metronidazole) 
caused by different bacterial species. 
Amikacin is an aminoglycoside antibiotic used 
for treatment of different types of bacterial infections. 
Chemical name of the amikacin is (2S)-4-amino-N-
[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-
amino-3,5-dihydroxy-6-(hydroxyl methyl)oxan-2-yl]
oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-
trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-
2-hydroxybutanamide – Figure  1b (Chemical-
Structure.34635.htmL). It is a semi-synthetic drug derived 
from kanamycin A with multidrug-resistant Gram-negative 
bacteria such as Pseudomonas aeruginosa, Acinetobacter, 
and Enterobacter (Grassi, Grassi, 1993; Tally et al., 1975; 
Brewer, 1977). Serratia marcescens and Providencia 
stuartii are also included in the spectrum. It can also be 
used to treat non-tubercular mycobacterial infections and 
tuberculosis (if caused by sensitive strains) when first-line 
drugs fail to control the infection (Pickering, Rutherford, 
1981; WHO, 2013). Amikacin may be combined with 
a beta-lactam antibiotic for empiric therapy for people 
with neutropenia and fever. It works by disrupts bacterial 
protein synthesis by binding to the 30S ribosome of 
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susceptible organisms similar to other aminoglycosides 
(Pickering, Rutherford, 1981). 
Various methods have been reported for analysis of 
cefepime (Spectrophotometry: Rambabu, Jyothirmayee, 
Naga Raju, 2012; Elazazy, Shalaby, 2012; Khare et al., 
2012; Sujith, Abraham, Divakar, 2010; Nanda et al., 
2012; Chafle, 2013; El-Shanawany et al., 2014; Patel 
et al., 2015a; Papanna, Krishnegowda, Nagaraja, 2015; 
Kant et al., 2015; Bhupendra, Bhuyan, Sinha, 2011; 
Chromatography: Sunitha et al., 2013; Dave Vimal, 2012; 
Patil et al., 2012; Khan, Iqbal, Khattak, 2012; Medina et 
al., 2007; Patel et al. 2010; Panchal Vipul et al., 2014; 
Ashok,Veenaeesh, Siripurapu, 2013; Syama Sundar, 
Gurucharana Das, 2014; Bhavana et al., 2013; Abdel-
Aziz et al., 2014; Mughal et al., 2016; Chromatography: 
Sunitha et al., 2013; Dave Vimal, 2012; Patil et al., 2012; 
Ramakrishna et al., 2014; Behan, Punitha, Krishanan, 
2013; Khan, Iqbal, Khattak, 2012; Medina et al., 2007; 
Patel et al., 2010; Neelima et al., 2013;Patel et al., 2015b; 
Baririan et al., 2003; Panchal Vipul et al., 2014; Ashok 
et al., 2013; Syamsundar, Guruchana Das, 2014; Arayne, 
Sulthana, Nawaz, 2006; Bhavana et al., 2013; Trivedi, 
Kshtri, Patel, 2013; Abdel-Aziz et al., 2014) and along 
with other combination of drugs and few analytical 
methods have been reported with the amikacin drug 
(Spectrophotometry: Mugal et al., 2016; Omar et al., 
2013; Soltés, 1999, Omara, Amin, 2013; Ryan, 1984; 
Chromatography: Feng, et al., 2001; Mokh et al., 2014; 
Isoherranen, Soback, 1999; Bhatt et al., 2015). But there 
is only one spectrophotometry method reported for the 
analysis of both cefepime and amikacin in combination 
(Kalyani, Rao, 2016). So the present work is aimed to 
develop the HPLC methods for estimation of cefepime 
and amikacin in combination. Hence the present work 
focuses in developing the RP-HPLC methods for the 
estimation of cefepime and amikacin in combined dosage 
forms. 
EXPERIMENTAL
Chemicals and materials
Analytically pure cefepime and amikacin were 
obtained as gift sample from reputed Pharmaceutical 
companies. Methanol, acetonitrile, water (Merck, 
Mumbai, India) were of HPLC grade, while Acetate Buffer 
used for the preparation of mobile phase was of analytical 
grade (Merck Specialties Private Limited, Mumbai, 
India). The membrane filters 0.22 μm and syringe filters 
0.45 μm for the analysis were supplied by Millipores® 
(Millipores Ltd. Banglore). Formulations of Potentox 
(Injection vials) contains a combination of cefepime and 
amikacin containing labeled amount of cefepime - 500 mg 
and amikacin - 125 mg were procured from local market.
Equipment
The Liquid Chromatographic procedures were 
carried out on PEAK chromatographic system make 
HPLC, equipped with LC-P7000 binary gradient pumps, 
with variable wavelength programmable UV7000 detector 
and diode array detector. Rheodyne injector with 20 μL 
fixed loop was used for sample injection. Chromatographic 
integration and processing were carried out on PEAK 
Chromatographic Software version 1.06. Waters XTerra© 
RP- C-18 (250 mm x 4.6 mm, 5 μm) column is used as 
stationary phase for separation. Standard and sample 
drugs were weighed by using Denver electronic analytical 
balance (SI-234). 
Preparation of mobile phase
The mobile phase was prepared by mixing methanol: 
acetonitrile:acetate buffer 75:20 (v/v) ratio and 5% of 
acetate buffer was added to adjust the pH at 5.1. Mobile 
FIGURE 1 - Chemical structure of cefepime (a) and amikacin (b)
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phase was sonicated for 15 min and before use the mobile 
phase was filtered through 0.22 μm membrane filter.
Preparation of standard solutions
A stock solution of cefepime and amikacin was 
prepared by dissolving 100 mg of the drug in 100mL 
volumetric flask with methanol individually. Aliquots of 
this solution were suitably diluted with mobile phase to 
get working standard solutions of cefepime and amikacin 
in the concentration range of 2.5-25 μg/mL for amikacin 
and 10-100 μg/mL for cefepime.
Preparation of sample solution for assay
Ten vial (injection) formulations of Potentox 
consisting cefepime - 500 mg and amikacin - 125 mg were 
soaked in 5 mL diluents and were kept it for solubility for 
1 h. Then it was filtered to make up to 10 mL with same 
diluents to make 100 µg/mL stock solutions. From this by 
proper dilution a concentration of 30 µg/mL of cefepime 
and 7.50 µg/mL amikacin were prepared according to 
its label claim. The resultant solution was used for the 
simultaneous estimation of cefepime and amikacin in 
combined dosage forms.
Forced degradation studies
To perform the forced degradation study 50 mg drug 
was subjected to acidic, alkaline, oxidizing, thermal and 
photolytic conditions. For acidic degradation the drug 
was heated under reflux with 0.1 M HCl at 80 °C for 2 h 
and the mixture was neutralized. For alkaline degradation 
the drug was treated with 0.1 M NaOH at 80º C for 2 h 
and the mixture was neutralized. For degradation under 
oxidizing conditions the drug was heated under reflux with 
(30%, v/v) H2O2 at 80 °C for 2 h. For thermal degradation 
the powdered drug was exposed at 70 °C for 48 h. For 
photolytic degradation the powdered drug was exposed 
to sunlight for 48 h. The placebo was also subjected to the 
same stress conditions to determine whether any peaks 
arose from the declared excipients. After completion of 
the treatments the solutions were left to return to room 
temperature and diluted with solvent mixture to furnish 
30 µg/mL concentrated solutions. The purity of the drug 
peak obtained from the stressed sample was measured by 
UV detector and compares the chromatogram of untreated 
drugs in tablet solution. 
RESULTS AND DISCUSSION
Method development
After optimizing several conditions for determination 
of cefepime and amikacin mobile phase consisting 
of Methanol: Acetonitrile: Acetate Buffer 75:20:05 
(v/v) at pH 5.1 was found to be satisfactory. The drugs 
gave symmetric and sharp peaks with Waters C-18 
(250 mm x 4.6 mm, 5 μm) column at 212 nm UV detector. 
The elution was achieved at 4.61min for amikacin and 
9.09min for cefepime with good resolution, theoretical 
plates and acceptable tailing factor (Figure 2). 
FIGURE 2 - Standard chromatogram of cefepime and amikacin
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Method validation
The method system suitability was evaluated by 
calculating the %RSD values of peak area, retention 
time, asymmetry and theoretical plates of five standard 
replicates. The experimental results (Table I) showed that 
the values were within the acceptable range indicating 
that the system was suitable for the intended analysis. 
Specificity results indicate that there was no interference 
from the excipients used and also from the mobile phase 
which proves that method is able to separate the main 
drugs from the degradation products. The specificity 
determined by using peak purity, resolution. Peak purity 
index shows that both cefepime and amikacin are clearly 
separated from the response of any interfering peak(s). 
Thus specificity study ensures the selectivity of the 
developed analytical method which is able to separate and 
quantify cefepime and amikacin in presence of different 
degradation products. Range of linearity of the proposed 
method was determined at different concentrations ranging 
from 2.5- 25µg/mL for amikacin and 10-100µg/mL 
for cefepime. The regression analysis equation was 
y = 8916.x + 36284 and correlation coefficient (r2) was 
0.999 for amikacin and y = 4442.x + 20680 and 
correlation coefficient (r2) was 0.999 for cefepime. Very 
low values for the statistical parameters like standard 
deviation of slope, intercept 102.80, 1594.67 for amikacin 
and 33.79, 2093.93 for cefepime indicate that there is 
linear relationship between the concentration and peak 
area. A very low standard deviation in quantitative analysis 
results 0.2505 for amikacin and 0.5906 for cefepime 
indicates that the quantity reported is accurate and 
acceptable. Hence the quantity of amikacin and cefepime 
can be accurately determined using the calibration graphs 
which were represented in Figure 3. 
Other key parameters like precision, ruggedness and 
robustness results are also within the limit. For amikacin 
%RSD is found to be 1.39, 0.17 and 1.363 for intraday, 
inter day and ruggedness studies. And % RSD of cefepime 
is found to be 0.51, 0.58 and 0.86 intraday, inter day and 
ruggedness respectively. Mean recovery 99.31%, 98.82% 
and 101.56% for amikacin and 100.53%, 100.44%, and 
101.19% for cefepime reveal that the intraday precision, 
inter day precision and ruggedness are in acceptable 
limit and hence is reliable. Accuracy of the method 
was studied by applying the developed method to the 
prepared synthetic mixtures of formulation excipients 
to which known amount of cefepime and amikacin were 
added. Mean recovery for amikacin was between 98.3-
100.37% and 98.58-101.37% for cefepime indicating the 
accuracy of the developed method. The percentage of 
change in results for robustness study includes 0.1-1.4% 
for amikacin and 0.14-0.89% for cefepime respectively. 
LOD value was found to be 0.003 µg/mL and LOQ was 
0.01 µg/mL for amikacin and 0.05 µg/mL and LOQ was 
0.20 µg/mL for cefepime respectively. 
When compared with literature data reported with 
methods of cefepime and amikacin, it was found that no 
RP-HPLC method was reported for forced degradation 
TABLE I - System suitability test results
Parameter Results
API Concentration Amikacin – 7.5 µg/mL 
Cefepime - 30 µg/mL
RT Amikacin– 4.61±0.0032 min 
Cefepime- 9.09±0.054 min
Resolution Amikacin– ……. 
Cefepime– 22.27±0.31
Area Amikacin– 104220±630 
Cefepime- 154431±595
TheoreticalPlates Amikacin– 9117±125 
Cefepime- 30242±240
TailingFactor Amikacin– 1.42±0.01 
Cefepime- 1.09±0.01
FIGURE 3 - Calibration graph of linearity of cefepime and amikacin
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studies. Dave Vimal described the RP-HPLC Method 
for Simultaneous Estimation of Cefepime Hydrochloride 
and Amikacin Sulfate in Injection Dosage Form (Dave 
Vimal, 2012).A statistical comparison of the quantitative 
determination of cefepime and amikacin shows that 
HPLC method is more accurate and precise than UV 
method (Bhatt et al., 2015). Hence the proposed method 
was found to be novel for stability indicating study of 
cefepime and amikacin as well as simultaneous estimation 
in formulation dosage form.
The solution stability of the standard and the test 
sample solution were checked by analyzing both the 
solutions at interval of 12 h till 24 h at room temperature. 
The results showed that both the retention time and area 
of both the drugs were unchanged and no significant 
degradation was observed within the indicated period 
which was sufficient for performing analytical process. 
There is good percentage of recovery when combined 
dosage form Potentox formulation was analyzed. In these 
results about 99.16% of assay for amikacin and 99.20% of 
assay for cefepime was found.
The proposed validated liquid chromatographic 
method was successfully applied to study the stress 
degradation property of cefepime and amikacin. The 
results of forced degradation studies are given in Table II 
and Figure4. Results indicate that this method is able to 
FIGURE 4 - Forced degradation chromatograms of cefepime and amikacin
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separate successfully and the degradation products are 
identified. The results reveal that drugs are sensitive to 
acidic and alkali conditions where more degradation 
occurred and stable in aqueous condition where there is 
no degradation observed. 
Application to pharmaceutical dosage form
The proposed method was applied for determination 
of drugs in the commercial pharmaceutical dosage forms. 
The results are statistically compared with those of reported 
methods (Omar et al., 2012, Chafle, 2013) with respect 
to accuracy and precision. The obtained mean recovery 
values are 99.16 ± 0.69 and 99.19 ± 0.59 for amikacin and 
cefepime respectively, as shown in Table III. F and t-tests 
are performed on this data and no significant difference 
was found between the calculated and theoretical values of 
both the proposed and the reported methods at 95%, 99% 
and 99.9% confidence level. This indicates good level of 
precision and accuracy. 
CONCLUSION
The developed method is simple, sensitive, accurate 
and precise. The proposed method is specific for 
determination of cefepime and amikacin in pure and as 
well as formulation analysis. The method was successfully 
used for determination of cefepime and amikacin in 
its pharmaceutical formulations and good recovery 
was found. As the method separates the drug from its 
degradation products, the method can be conveniently 
used for routine quality control analysis of cefepime and 
amikacin in industries for batch release.
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